POSTER SESSION IV Tuesday, March 25, 2003   —  1:00 - 4:30 PM Exhibit Hall A - C BREAST PATHOLOGY 9 Familial Breast Cancer: A Genetic and Immunohistochemical Study (161) E Lerma, E Honrado, J Palacios, C Pons, J Munoz, A Gallardo, C Rivas, O Diez, MC Alonso, J Benitez, J Prat Hospital Sant Pau. Autonomous University of Barcelona, Barcelona, Spain; Centro Nacional de Investigaciones Oncologicas, Madrid, Spain 10 Microsatellite Instability in Korean Early-Age Onset Sporadic Breast Carcinoma (179) IA Park, JO Lee, H-C Lee, SA Han Seoul National University College of Medicine, Seoul, Korea 11 P53 and Her2 neu Expression in Breast Carcinoma Occuring in Young Women (167) D Maru, LP Middleton, S Wang, V Valero, A Sahin U.T.M.D. Anderson Cancer Center, Houston, TX 12 Immunohistochemical Profile of Hereditary Breast Cancer Not Attributable to BRCA1 and BRCA2 Mutations. A Tissue Microarray Study (178) J Palacios, E Honrado, C Rivas, E Lerma, L Sanchez, O Diez, MC Alonso, J Prat, J Benitez Centro Nacional de Investigaciones Oncologicas, Madrid; Hospital de Leon, Leon; Fundacion Jimenez Diaz, Madrid; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain 13 High Topoisomerase II Alpha Expression in HER2-Negative, ER-Negative Breast Tumors Is Associated with p53 Mutations (174) RE Mueller, RK Parkes, FP O'Malley Samuel Lunenfeld Research Institute; Mount Sinai Hospital; University of Toronto, ON, Canada 14 Quantitative Analysis of Breast Cancer Tissue Microarrays Shows Both High and Normal Levels of HER2 Expression Are Associated with Poor Outcome (94) RL Camp, M Dolled-Filhart, B King, DL Rimm Yale University, School of Medicine, New Haven, CT 15 Her2/neu Amplification in Breast Carcinoma: Comparison of Real-Time Quantitative Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC) and Flourescent In Situ Hybridization (FISH) (204) MB Smolkin, P Mahadevia, M Vuolo, KH Ramesh, L Cannizzaro, H Ratech, C Schultz Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY 16 Comparison of HER2/neu Status Evaluated by FISH and Two Methods of Quantitative PCR (177) FP O'Malley, T Thomson, JA Julian, R Cosby, C Have, S Dubois, T Whelan, K Gelmon, I Andrulis Mount Sinai Hospital, Toronto, ON, Canada; McMaster University, Hamilton, ON, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Samuel Lunenfeld Research Institute, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada 17 Automated Chromogenic In Situ Hybridization (CISH) for Detection of HER2 Gene Amplification (212) R Tubbs, J Pettay, M Skacel, D Hicks, J Mele, R Powell, T Chen, H Nita, T Grogan, J Hainfeld Cleveland Clinic, Cleveland, OH; Nanoprobes, Yaphank, NY; Ventana Medical Systems Intl, Tucson, Az 18 Evaluation of HER-2/neu Gene Status in Breast Cancer by Chromogenic In Situ Hybridization: Comparison with Immunohistochemistry (154) S Kounelis, N Kapranos, N Malamos, E Kokka, H Arvanitis, E Kouri H.Venizelou Hospital, Athens, Greece; A.Fleming, Athens, Greece 19 Use of Chromogenic In-Situ Hybridization (CISH) in Determining Her2 Status (145) M Jundi, S Selim, S Phillips, FU Garcia Drexel University School of Medicine, Philadelphia, PA 20 HER2 Amplification: Correlation of Chromogenic In Situ Hybridization (CISH) with Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) (219) CR Wixom, EA Albers, N Weidner University of California, San Diego, San Diego, CA 21 Comparison of HER-2/neu Status by FISH in a Central Laboratory with Immunohistochemistry Determined in Local Laboratories (182) MF Press, G Sauter, L Bernstein, M Mirlacher, I Villalobos, J Zhou, A Riva, J-M Nabholtz, DJ Slamon USC/Norris Comprehensive Cancer Center, Los Angeles, CA; University of Basel, Basel, Switzerland; Breast Cancer International Research Group, Paris, France; UCLA, Los Angeles, CA 22 FISH and IHC HER2 Testing in Patients with Metastatic Breast Cancer: Concordance Issues between Local Laboratories and a Central Reference Laboratory (82) SM Anderson, E Gilkerson, P Klein Laboratory Corporation of America, Research Triangle Park, NC; Genentech, Inc., South San Francisco, CA 23 Evaluation of HER-2/neu Status by Fluorescent In Situ Hybridization (FISH) in a Reflex Model of HER-2/neu Testing in a Tertiary Academic Setting (104) EF Cosar, KP Siziopikou Loyola University Medical Center, Maywood, IL 24 Strong Her-2/neu Protein Overexpression by IHC Often Does Not Predict Oncogene Amplification by FISH Assay (130) L Hammock, C Cohen, C Phillips, M Lewis Emory University Hospital, Atlanta, GA 25 Concordance of Epidermal Growth Factor Receptor (EGFR) and HER-2/NEU (H2N) Protein Expression and Gene Amplification in Invasive, Poorly-Differentiated Breast Carcinomas (202) SJ Shin, E Hyjek, E Early, DM Knowles Weill Medical College of Cornell University, New York, NY 26 Discordance of HER2 and p53 between Primary and Asynchronous Metasatic/Recurrent Breast Cancers: Immunohistochemical and Molecular Analysis (196) Y Sedkido, S Umemura, RY Osamura Tokai University, School of Medicine, Isehara, Kanagawa, Japan 27 c-erbB-2 (HER2/neu) in Infiltrative Lobular Carcinoma: Dissociation between Immunohistochemistry and Fluorescence In Situ Hybridization (170) W McDonald, Y Chen, C Zaloudek, G Magrane, F Waldman UCSF; UCSF, San Francisco, CA 28 Intracellular Patterns of Her-2/neu, ras, and Ploidy Abnormalities in Primary Human Breast Cancers Predict Clinical Disease Free Survival (198) SE Shackney, CA Smith, A Pollice, K Brown, R Day, T Julian, Y Liu, JF Silverman Allegheny General Hospital, Pittsburgh, PA; University of Pittsburgh, Pittsburgh, PA 29 Male Breast Cancer: Correlation between Clinico-Pathologic Features and c-erbB-2 Status (114) R Fonseca, S Andre, C Laranjeira, A Tomas, A Pinto, I Fonseca Instituto Portugues Oncologia, Lisboa, Portugal 30 The Predictive Value of Her2/neu Status on Clinical Outcome in Tamoxifen-Treated Breast Cancer Patients (131) W Hanna, JW Wong, J Zubovits, M Trudeau Sunnybrook-Women's College Health Sciences Centre, University of Toronto; Toronto-Sunnybrook Regional Cancer Centre, Toronto, ON, Canada